You are a helpful, respectful, and honest assistant. Always answer as helpfully as possible, while being safe. Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content. Please ensure that your responses are socially unbiased and positive in nature. If a question does not make any sense or is not factually coherent, explain why instead of answering something not correct. If you don't know the answer to a question, please don't share false information.
What is Which of the following is a new drug available to treat multi drug resistant tuberculosis? and explain in detail?
Ans. a. Bedaquiline (Ref: Harrison 19/e p1115. 205e- 7)Two novel drugs belonging to two new antibiotic classes--the diarylquinoline bedaquiline and the nitroimidazole delamanid--have recently been approved for use in severe cases of MDR-TB by stringent regulatory authorities."Two novel drugs belonging to two new antibiotic classes--the diarylquinoline bedaquiline and the nitroimidazole delamanid--have recently been approved for use in severe cases of MDR-TB by stringent regulatory authorities (the L .S. Food and Drug Administration (FDA} and the European Medicine Agency (EMA] in the case of bedaquiline; the EM A and the Pharmaceuticals and Medical Devices Agency of Japan in the case of delamanid). "-- Harrison 19/e p1115BedaquilineBedaquiline is a new diarylquinoline with a novel mechanism of action: inhibition of the mycobacterial ATP synthetase proton pumpQ.It is bactericidal for drug-susceptible and MDR strains of M. tuberculosisQ.Mechanism of action:Inhibition of the mycobacterial ATP synthetase proton pump.Therapeutic Uses:Provisional recommendation for the use of bedaquiline for 24 weeks in adults with laboratory-confirmed pulmonary MDR-TB when no other effective treatment regimen can be provided.Side-Effects:Arrhythmias (induce long QT syndrome by blocking the hERG channel)Resistance:Resistance has been reported and is due to point mutations in the atpE gene encoding for subunit c of ATP synthetase.Anti-Tubercular DrugsFirst line (WHO Group 1)Second lineThird line* EthambutolQ (EMB or E)* IsoniazidQ (INH or H )* PyrazinamideQ (PZA or Z)* RifampicinQ (RMP or R)* StreptomycinQ (SM or S)* Second line drugs (WHO groups 2, 3 & 4) are only used to treat disease that is resistant to first line therapy, i.e., for extensively drug-resistant tuberculosis (XDR-TB) or multidrug- resistant tuberculosis (MDR-TB).* Aminoglycosides (WHO group 2): Amikacin, kanamycinQ* Polypeptides (WHO group 2): Capreomycin, viomycin, enviomycinQ* Fluoroquinolones (WHO group 3): Ciprofloxacin, levofloxacin, moxifloxacinQ* Thioamides (WHO group 4): Ethionamide, prothionamideQ* CycloserineQ (WHO group 4)* TerizidoneQ (WHO group 5)* Third-line drugs (WHO group 5) include drugs that may be useful, but have doubtful or unproven efficacy.* RifabutinQ* ClarithromycinQ* LinezolidQ* ThioacetazoneQ* ThioridazineQ* Arginine* Vitamin D* BedaquilineQ* DeiamanidQ